194 related articles for article (PubMed ID: 34454530)
1. Prognostic significance of the aberrant expression of neuroendocrine markers in melanomas.
Wu Y; Lai Y; Zhang M; Li Z
Diagn Pathol; 2021 Aug; 16(1):78. PubMed ID: 34454530
[TBL] [Abstract][Full Text] [Related]
2. Aberrant intermediate filament and synaptophysin expression is a frequent event in malignant melanoma: an immunohistochemical study of 73 cases.
Romano RC; Carter JM; Folpe AL
Mod Pathol; 2015 Aug; 28(8):1033-42. PubMed ID: 26022451
[TBL] [Abstract][Full Text] [Related]
3. Role of Synaptophysin, Chromogranin and CD56 in adenocarcinoma and squamous cell carcinoma of the lung lacking morphological features of neuroendocrine differentiation: a retrospective large-scale study on 1170 tissue samples.
Kriegsmann K; Zgorzelski C; Muley T; Christopoulos P; Thomas M; Winter H; Eichhorn M; Eichhorn F; von Winterfeld M; Herpel E; Goeppert B; Stenzinger A; Herth FJF; Warth A; Kriegsmann M
BMC Cancer; 2021 May; 21(1):486. PubMed ID: 33933015
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of neuroendocrine markers in renal cell carcinoma.
Ronkainen H; Soini Y; Vaarala MH; Kauppila S; Hirvikoski P
Diagn Pathol; 2010 May; 5():28. PubMed ID: 20462442
[TBL] [Abstract][Full Text] [Related]
5. Application of INSM1 in Diagnosis and Grading of Laryngeal Neuroendocrine Carcinoma.
Yuan C; Jiao F; Zhai C; Zhang J; Wang S; Zhu L
Laryngoscope; 2021 Oct; 131(10):E2662-E2668. PubMed ID: 33847383
[TBL] [Abstract][Full Text] [Related]
6. Correlation of three immunohistochemically detected markers of neuroendocrine differentiation with clinical predictors of disease progression in prostate cancer.
Ather MH; Abbas F; Faruqui N; Israr M; Pervez S
BMC Urol; 2008 Dec; 8():21. PubMed ID: 19115997
[TBL] [Abstract][Full Text] [Related]
7. Analysis of Clinicopathological Features and Prognostic Factors in 39 Cases of Bladder Neuroendocrine Carcinoma.
Zhou HH; Liu LY; Yu GH; Qu GM; Gong PY; Yu X; Yang P
Anticancer Res; 2017 Aug; 37(8):4529-4537. PubMed ID: 28739749
[TBL] [Abstract][Full Text] [Related]
8. Proliferation indices of phosphohistone H3 and Ki67: strong prognostic markers in a consecutive cohort with stage I/II melanoma.
Nielsen PS; Riber-Hansen R; Jensen TO; Schmidt H; Steiniche T
Mod Pathol; 2013 Mar; 26(3):404-13. PubMed ID: 23174936
[TBL] [Abstract][Full Text] [Related]
9. Expression of neuroendocrine markers in non-neuroendocrine endometrial carcinomas.
Moritz AW; Schlumbrecht MP; Nadji M; Pinto A
Pathology; 2019 Jun; 51(4):369-374. PubMed ID: 31040050
[TBL] [Abstract][Full Text] [Related]
10. Aberrant expression of epithelial and neuroendocrine markers in alveolar rhabdomyosarcoma: a potentially serious diagnostic pitfall.
Bahrami A; Gown AM; Baird GS; Hicks MJ; Folpe AL
Mod Pathol; 2008 Jul; 21(7):795-806. PubMed ID: 18487991
[TBL] [Abstract][Full Text] [Related]
11. Simultaneous endocrine expression and loss of melanoma markers in malignant melanoma metastases, a retrospective analysis.
Steppert C; Krugmann J; Sterlacci W
Pathol Oncol Res; 2020 Jul; 26(3):1777-1779. PubMed ID: 31654227
[TBL] [Abstract][Full Text] [Related]
12. [Analysis of clinicopathological features of intestinal neuroendocrine neoplasms].
Gao W; Liu SM; Lu HZ; Liang J; Yuan YL; Liu XY
Zhonghua Zhong Liu Za Zhi; 2012 Jun; 34(6):450-6. PubMed ID: 22967448
[TBL] [Abstract][Full Text] [Related]
13. SOX11 is a sensitive and specific marker for pulmonary high-grade neuroendocrine tumors.
Yu L; Dong Y; Xue J; Xu S; Wang G; Kuang D; Duan Y
Diagn Pathol; 2022 Jan; 17(1):2. PubMed ID: 34996493
[TBL] [Abstract][Full Text] [Related]
14. P53, Somatostatin receptor 2a and Chromogranin A immunostaining as prognostic markers in high grade gastroenteropancreatic neuroendocrine neoplasms.
Nielsen K; Binderup T; Langer SW; Kjaer A; Knigge P; Grøndahl V; Melchior L; Federspiel B; Knigge U
BMC Cancer; 2020 Jan; 20(1):27. PubMed ID: 31924180
[TBL] [Abstract][Full Text] [Related]
15. Expression of novel neuroendocrine marker insulinoma-associated protein 1 (INSM1) in genitourinary high-grade neuroendocrine carcinomas: An immunohistochemical study with specificity analysis and comparison to chromogranin, synaptophysin, and CD56.
Chen JF; Yang C; Sun Y; Cao D
Pathol Res Pract; 2020 Jun; 216(6):152993. PubMed ID: 32381384
[TBL] [Abstract][Full Text] [Related]
16. CD56 expression in basaloid anal squamous cell carcinoma - A potential diagnostic pitfall.
Madahian S; Judelson R; Zhu X; Meng X; Dresser K; Hutchinson L; Bledsoe JR
Ann Diagn Pathol; 2021 Aug; 53():151758. PubMed ID: 33989959
[TBL] [Abstract][Full Text] [Related]
17. Microphthalmia transcription factor in malignant melanoma predicts occult sentinel lymph node metastases and survival.
Naffouje S; Naffouje R; Bhagwandin S; Salti GI
Melanoma Res; 2015 Dec; 25(6):496-502. PubMed ID: 26317170
[TBL] [Abstract][Full Text] [Related]
18. INSM1 is a novel prognostic neuroendocrine marker for luminal B breast cancer.
Razvi H; Tsang JY; Poon IK; Chan SK; Cheung SY; Shea KH; Tse GM
Pathology; 2021 Feb; 53(2):170-178. PubMed ID: 32951906
[TBL] [Abstract][Full Text] [Related]
19. Pulmonary neuroendocrine tumors: study of 90 cases focusing on clinicopathological characteristics, immunophenotype, preoperative biopsy, and frozen section diagnoses.
Yeh YC; Chou TY
J Surg Oncol; 2014 Mar; 109(3):280-6. PubMed ID: 24301337
[TBL] [Abstract][Full Text] [Related]
20. The prognostic significance of neuroendocrine markers and somatostatin receptor 2 in hepatocellular carcinoma.
Murakami K; Kumata H; Miyagi S; Kamei T; Sasano H
Pathol Int; 2021 Oct; 71(10):682-691. PubMed ID: 34320691
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
